Showing 8 posts of 8 posts found.

AS spine fusion

Novartis’ Cosentyx shows benefits in Phase III AS trials

January 4, 2016
Research and Development, Sales and Marketing Cosentyx, Novartis, Secukinumab, ankylosing spondylitis

Novartis says results from two Phase III studies for Cosentyx in ankylosing spondylitis (AS) showing significant clinical improvements versus placebo.Results …


Novartis psoriasis drug shows three-year efficacy

October 12, 2015
Cosentyx, EADV, Novartis, Secukinumab, psoriasis

Novartis has announced new trial data confirming the efficacy of Cosentyx in patients with moderate-to-severe plaque psoriasis. The results of …


Novartis’s secukinumab meets Phase 3 goals

October 1, 2015
Research and Development Novartis, Secukinumab, arthritis

Novartis has announced that its secukinumab medication for treatment of psoriatic arthritis (PsA), met its primary endpoint in the pivotal …

Novartis spends $200m on pain firm Spinifex

June 29, 2015
Sales and Marketing Cosentyx, EMA401, Novartis, Secukinumab, spinifex

Novartis is spending $200 million to increase its presence in pain management through the purchase of US-Australian biotech Spinifex Pharmaceuticals.  …


NICE green-light for Novartis skin drug

May 29, 2015
Sales and Marketing Cosentyx, IL-17, NICE, Novartis, Secukinumab

NICE has released positive draft guidance for three treatments, including the first in a new generation of psoriasis drugs. Novartis’ …

Novartis and Abbott start year with strong Q1 sales

April 23, 2015
Sales and Marketing Abbott, Amgen, Cosentyx, GSK, Neupogen, Novartis, Secukinumab, Zarxio, biosimilar, filgrastim, financials

Novartis and Abbott have both posted strong first-quarter results and made bullish predictions about their financial performance in 2015. Novartis …

Novartis image

Novartis gets FDA approval for psoriasis drug

January 22, 2015
Sales and Marketing Cosentyx, European Commission, FDA, Novartis, Secukinumab, psoriasis

The US Food and Drug Administration (FDA) has shown Novartis’ skin condition drug Cosentyx the green light to treat patients …

Novartis image

Novartis to present inflammatory data

November 10, 2014
Business Services AS, Novartis, PSA, Secukinumab, acr

Novartis is to present data from four pivotal Phase III trials in two debilitating inflammatory diseases at the American College …

Latest content